English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Background: Weighing in at around 3 pounds, the liver is the body’s second largest organ; only the skin is larger and heavier. The liver performs many essential functions related to digestion, metabolism, immunity, and the storage of nutrients within the body. These functions make the liver a vital organ without which the tissues of the body would quickly die from lack of energy and nutrients. Fortunately, the liver has an incredible capacity for regeneration of dead or damaged tissues; it can grow as quickly as a cancerous tumor to restore its normal size and function. Objective: to evaluate the levels of fibrosis regression by ARFI in the patients with successful eradication of chronic hepatitis C virus after 12 weeks and 24 weeks after completion of treatment with direct acting antiviral drugs (sustained virological response, SVR 12 and SVR 24). Patients and Methods: This prospective and observational cohort study was conducted during the period between June 2016 and February 2019 in total of 60 individuals at Al-Azhar (Al-Hussein) Hospital and National Search Institute in Cairo divided into three groups. Results: Results show that the median fibrosis degree measured by ARFI in all patients was significantly decreased after HCV eradication with 100 % success in cure rate and 16.5% of patients failed to regress fibrosis. Conclusion: A disappointing percentage (16.5%) failure in fibrosis regression although reaching a sustained virological response.

Assessment of Degree of Fibrosis in Chronic Hepatitis C Virus Patients Treated with Direct Acting Antiviral Agents